Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCHE | P06276 | 1/20 | 0.66 |
| ▸ | HTT | P42858 | 2/20 | 0.58 |
| ▸ | POLB | P06746 | 2/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.56 |
| ▸ | LMNA | P02545 | 3/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.54 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.54 |
| ▸ | MAPT | P10636 | 3/20 | 0.52 |
| ▸ | THRB | P10828 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6304380 | 0.93 | BCHE (0.69) | BCHEHTTSMN1; SMN2LMNACYP1A2 | |
| SCHEMBL2086623 | 0.87 | BCHE (0.62) | BCHEHTTPOLBSMN1; SMN2LMNA | |
| SCHEMBL5144365 | 0.86 | BCHE (0.61) | BCHEHTTPOLBSMN1; SMN2LMNA | |
| SCHEMBL6297783 | 0.85 | BCHE (0.65) | BCHEHTTPOLBSMN1; SMN2LMNA | |
| SCHEMBL19540734 | 0.84 | BCHE (0.64) | BCHEHTTSMN1; SMN2LMNACYP1A2 | |
| SCHEMBL15173223 | 0.83 | BRD4 (0.49) | BCHEHTTPOLBCYP1A2CYP2C9 | |
| SCHEMBL5146214 | 0.83 | BCHE (0.57) | BCHEHTTPOLBSMN1; SMN2LMNA | |
| SCHEMBL4640990 | 0.82 | BCHE (0.87) | BCHESMN1; SMN2LMNAALDH1A1 | |
| SCHEMBL13405878 | 0.82 | HTT (0.84) | HTTPOLBSMN1; SMN2LMNAKDM4E | |
| SCHEMBL10721736 | 0.82 | BCHE (0.55) | BCHEHTTSMN1; SMN2LMNACYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2670733-B1 | N-HYDROXYBENZAMIDE DERIVATIVES AS HDAC INHIBITORS AND THERAPEUTIC METHODS USING THE SAME | UNIV ILLINOIS (US) | 2019-04-10 | — | — | EP | disclosed |
| US-20140128408-A1 | HDAC INHIBITORS AND THERAPEUTIC METHODS USING THE SAME | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2014-05-08 | — | — | US | disclosed |
| US-20140128408-A1 | HDAC INHIBITORS AND THERAPEUTIC METHODS USING THE SAME | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2014-05-08 | — | — | US | disclosed |
| EP-0869787-A4 | VITRONECTIN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORP (US) | 1999-03-24 | — | — | EP | disclosed |
| EP-0869787-A1 | VITRONECTIN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 1998-10-14 | — | — | EP | disclosed |
| WO-1997024119-A1 | VITRONECTIN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 1997-07-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140128408-A1 | HDAC INHIBITORS AND THERAPEUTIC METHODS USING THE SAME | HDAC1, HDAC9, HDAC8 | BCHE 1019/4885HTT 134/4885POLB 1923/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.